Skip to main content
. Author manuscript; available in PMC: 2013 Jun 19.
Published in final edited form as: European J Org Chem. 2011 Oct 19;2011(33):6641–6648. doi: 10.1002/ejoc.201101063

Table 1.

Evaluation of C-NE3TA-trastuzumab conjugate[a] and C-NOTA-trastuzmab Conjguate[b] for Radiolabling efficiency (%) with 90Y and 177Lu (0.25M NH4OAc, pH 5.5, RT) using ITLC or HPLC (Parenthesis).

90Y 177Lu
Time
(min)		 C-NE3TA-
trastuzumab		 C-NOTA-
trastuzumab		 C-NE3TA-
trastuzumab		 C-NOTA-
trastuzumab
1 23.3 ± 2.7
(22.9 ± 2.0)		 2.9 ± 0.2 13.5 ± 0.7
(10.5 ± 0.8)		 1.1 ± 0.2
5 46.6 ± 3.5
(39.3 ± 3.4)		 13.0 ± 8.2 21.8 ± 0.6
(18.0 ± 0.2)		 3.7 ± 1.6
10 60.1 ± 0.7
(49.9 ± 1.7)		 10.1 ± 4.8 26.8 ± 0.5
(21.7 ± 0.2)		 5.0 ± 1.8
20 73.9 ± 2.6
(61.8 ± 1.6)		 8.6 ± 0.0 32.1 ± 1.3
(24.7 ± 0.7)		 9.8 ± 2.1
30 81.6 ± 1.6
(66.1 ± 1.1)		 8.7 ± 2.8 33.6 ± 1.7
(26.0 ± 0.4)		 13.3 ± 1.1
60 88.9 ± 1.7
(71.9 ± 1.3)		 16.1 ± 5.4 37.7 ± 1.6
(29.0 ± 0.2)		 22.9 ± 4.5
[a]

Radiolabeling efficiency (mean ± standard deviation %) was measured in triplicate using HPLC and ITLC.

[b]

Radiolabeling efficiency (mean ± standard deviation %) was measured in duplicate using ITLC.